Loading...
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of improved therapies with novel mechanisms of cell killing. A current clinical target for B-cell lymphoma is CD22, a B-cell–specific member of...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890185/ https://ncbi.nlm.nih.gov/pubmed/20181615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-12-257386 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|